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ABSTRACT 
Myostatin, a key regulator of muscle mass in vertebrates, is biosynthesised as a latent precursor in 
muscle and is activated by sequential proteolysis of the pro-domain. To investigate the molecular 
mechanism by which pro-myostatin remains latent, we have solved the structure of unprocessed pro-
myostatin and analysed the properties of the protein in its different forms. Crystal structures and SAXS 
analyses show that pro-myostatin adopts an open, V-shaped structure with a domain-swapped 
arrangement. The pro-mature complex, after cleavage of the furin site, has significantly reduced activity 
compared with mature growth factor and persists as a stable complex that is resistant to the natural 
antagonist follistatin. The latency appears to be conferred by a number of distinct features that 
collectively stabilise the interaction of the pro-domains with the mature growth factor, enabling a 
regulated step-wise activation process, distinct from the prototypical pro-TGF-β1. These results provide 
a basis for understanding the effect of missense mutations in pro-myostatin and pave the way for the 
design of novel myostatin inhibitors.   
INTRODUCTION 
The pathological outcomes which arise as a result of aberrant cellular signalling, including cancer, 
highlight the importance of spatial and temporal signal control in biology. One of the ways that 
signalling protein activity can be controlled is by the expression of these molecules as inactive, or latent 
forms, with activation occurring only where and when a timely response is required. Controlled 
proteolysis is a common mechanism of activation for the pro-forms of bioactive molecules and is well 
characterised in many biological systems, from the proteases of the digestive system, to secreted growth 
factors. Controlled post-translational activation allows the proteins to be expressed and stored in a 
precursor form and then rapidly activated in response to external stimuli.    
Myostatin, (also called growth and differentiation factor 8; GDF8), of the transforming growth factor β 
(TGF-β) superfamily of signalling proteins is a negative regulator of skeletal muscle growth. 
Dysfunctional myostatin signalling liberates muscle growth and yields the characteristic hyper-
muscular phenotypes seen in myostatin-null animals (McPherron & Lee, 1997; McPherron et al, 1997). 
Unsurprisingly, manipulation of myostatin signalling has become an attractive prospect for increasing 
functional muscle mass in the context of muscular atrophic disorders including muscular dystrophy, 
sarcopenia and cancer-associated cachexia (Smith & Lin, 2013). 
Myostatin itself is a relatively well characterised member of the TGF-β superfamily, and like other 
members, is synthesised as an inactive precursor (pro-myostatin), with N-terminal signal peptide and 
pro-domain, and C-terminal growth factor (GF) domain. The precursor forms a covalently linked dimer 
through a conserved disulfide in the GF domain (Lee & McPherron, 2001; Jiang et al, 2004; McPherron 
& Lee, 1997). Cleavage of pro-domains by furin-like pro-protein convertases, either during secretion 
or extracellularly, yields a non-covalent complex of the dimeric mature GF with its associated pro-
domains (pro-myostatin complex) (Wolfman et al, 2003; Sengle et al, 2008). The non-covalent 
association of pro-domains is typically thought to retain myostatin in a latent state by occluding receptor 
epitopes and rendering it unable to engage its receptors (Jiang et al, 2004; Wolfman et al, 2003). In 
contrast to pro-TGF-β1 which undergoes integrin-driven mechanical activation, a secondary proteolytic 
cleavage within the pro-domain by BMP1/Tolloid (TLD) family metalloproteases liberates the full 
signalling capacity of mature myostatin (Wolfman et al, 2003; Shi et al, 2011). The liberated, mature 
myostatin will form a heterotetrameric complex with two activin responsive type II receptors (ActIIRA 
or ActIIRB) and two of either activin type I (ALK4) or TGF-β type I (ALK5) receptors to initiate 
signalling (Rebbapragada et al, 2003; Lee & McPherron, 2001). Assembly of a competent receptor 
complex results in SMAD 2/3 phosphorylation by the type I receptors and translocation of SMADs to 
the nucleus for modulation of gene expression (Huang et al, 2011). 
At present, three structures of pro-TGF-β superfamily members are available; pro-TGF-β1, pro-activin 
A and pro-BMP9, all of which display unique arrangements of pro and mature GF domains (Mi et al, 
2015; Shi et al, 2011; Wang et al, 2016). As mentioned above, in some cases the pro-domain confers 
latency to the pro-form, as is known to be the case for pro-TGF-β1 and pro-myostatin. Conversely, pro-
activin A and pro-BMP9 complexes show equivalent signalling activity to their free mature GFs, 
suggesting a weak, non-inhibitory association of pro-domains (Wang et al, 2016; Mi et al, 2015). TGF-
β1, which forms a latent complex with its furin-cleaved pro-domains, utilises an inter-molecular 
disulfide bond to cross-link pro-domains and enclose the dimeric GF in an inhibitory stranglehold, 
requiring mechanical or proteolytic activation (Shi et al, 2011). Pro-myostatin lacks the cysteines 
needed for this this latency conferring covalent linkage, and as such the structural basis for its latency 
remains unclear. 
Myostatin is known to be secreted both as an unprocessed precursor and a furin cleaved complex, with 
the former thought to constitute the major pool of myostatin in the extracellular space of skeletal muscle 
(Anderson et al, 2008). Within the extracellular environment of muscle, latent pro-myostatin is localised 
to the extracellular matrix (ECM), through pro-domain mediated interactions with heparan sulfate 
proteoglycans and latent TGF-β binding proteins (LTBPs) (Sengle et al, 2011; Anderson et al, 2008). 
Soluble antagonists of the mature GF, including follistatin, FSTL3, GASP1, GASP2 and decorin, 
contribute an additional layer of control, within an already complex regulatory environment (Cash et 
al, 2009; Walker et al, 2015; Miura et al, 2006). 
Targeted inhibition of myostatin signalling to enhance muscle growth continues to present a 
considerable clinical challenge. A number of myostatin binding antibodies, designed to suppress 
myostatin signalling in the context of muscular atrophic disorders, have failed to meet primary clinical 
endpoints in phase II trials (bimagrumab by Novartis and PINTA 745 by Atara) (Novartis, 2016; Atara 
Bio, 2015). Similarly, an ActRIIB receptor-Fc fusion (ACE-031 by Acceleron) was withdrawn from 
phase II trials due to safety concerns (Smith & Lin, 2013). To date, no myostatin inhibitors are approved 
for clinical use. It seems probable that attempts to block mature myostatin signalling are hampered by 
the cross-reactivity of soluble antagonists with structurally related TGF-β superfamily growth factors. 
This is particularly likely for soluble receptor-Fc fusions, or ligand-traps, which exhibit a natural 
promiscuity towards different TGF-β superfamily ligands. 
The difficulties associated with targeting the mature, active growth factor, make the more structurally 
diverse pro-forms of these proteins potentially more meaningful targets for intervention. Aside from 
lower conservation in sequence and structure, the pro-forms show increased abundance and longevity 
over the mature growth factors which are difficult to target due to the short temporal and spatial window 
within which they exert their paracrine signal. Stabilisation of a latent conformation of the pro-
myostatin complex and/or inhibition of proteolytic processing of the precursor could offer alternate 
routes to selective neutralisation of myostatin signalling. Understanding the mechanism by which the 
pro-domains render the growth factor inactive will be essential for these efforts.  
Here we present crystal structures of unprocessed human pro-myostatin, the major extracellular storage 
form in skeletal muscle tissue. This structure reveals a  unique arrangement of GF and pro-domains to 
confer latency within the TGF-β superfamily. An unexpected ‘open-armed’ conformation, with no 
direct interaction between the arm/shoulder-domains of the domain-swapped dimer, makes pro-
myostatin structurally distinct from latent pro-TGF-β1. This structure allows us to understand the 
determinants of latency and reveals features that enable controlled activation of myostatin. It provides 
us also with a rational basis for the development of the next generation of myostatin inhibitors.  
RESULTS 
Production and characterisation of human pro-myostatin 
Unprocessed human pro-myostatin was expressed as inclusion bodies in E. coli and subsequently 
solubilised, refolded and purified. As expected, the protein migrated on non-reduced SDS-PAGE as a 
disulfide-linked dimer and analysis by size exclusion chromatography and multi-angle light scattering 
(SEC-MALS) confirms the dimeric state under native conditions, with a molecular weight of 84.5 ± 
0.005 kDa (cf. calculated from sequence 85.4 kDa) (Figure 1A). 
For functional analysis, an engineered variant of pro-myostatin was generated in which the native furin 
cleavage site was replaced by a HRV-3C protease site, to allow us to study the effects of proteolytic 
processing of the precursor in vitro. The HRV-3C cleaved pro-myostatin was shown, by SEC-MALS, 
to form a stable non-covalent complex with a molecular mass of 83.4 ± 0.008 kDa, consistent with the 
expected mass for a complex of a mature GF dimer with two associated pro-domains (Figure 1A). Pro-
domain cleavage appears to proceed via a semi-cleaved intermediate, a small proportion of which 
persists in the final preparation, even after incubation with a molar excess of protease. The mature GF 
dimer could be purified from the complex by reverse phase chromatography, and was shown to activate 
SMAD2/3 signalling in HEK293T cells with high potency  (EC50: 0.1 nM, 95% C.I [0.09, 0.12]) (Figure 
1B). While uncleaved pro-myostatin was entirely inactive at the highest concentrations of protein tested, 
the HRV-3C cleaved complex shows low-level signalling activity, more than 100-fold less potent than 
the purified mature GF (EC50: 17 nM, 95% C.I [11, 32]) (Figure 1B). Bioactivity of the pro-myostatin 
complex, traditionally thought to circulate as an entirely latent complex in serum, has been observed 
previously by Szlama et al, who interpret the unexpected activity as the result of partial dissociation of 
the pro-domains under assay conditions (Szláma et al, 2013). This is in clear contrast to both pro-TGF-
β1 and pro-activin A complexes. Latent pro-TGF-β1 shows no activity under similar assay conditions, 
whereas the pro-activin A pro-domain exerts only a marginal inhibitory effect at the picomolar 
concentrations where the mature growth factor has been shown to be active (Shi et al, 2011; Wang et 
al, 2016).  
To evaluate whether cleavage at the furin-site causes significant conformational change of the protein, 
we analysed both uncleaved and cleaved pro-myostatins using small angle X-ray scattering (SAXS). 
The scattering profiles were very similar in both cases and the estimated radii of gyration (Rg,uncleaved 
=40.0 Å, Rg,cleaved =38.9 Å) and maximum particle dimensions (Dmax,uncleaved=140.6 Å, Dmax,cleaved=146.6 
Å) of the proteins are very similar (Figures 2A, 2B, Appendix Figure S1). This suggests that no drastic 
re-organisation of the protein is triggered by the proteolysis of the furin site, consistent with the 
significant latency of this complex in bioassays.  
To study the stability of the cleaved pro-myostatin complex further, we used biolayer interferometry 
(BLI) to monitor the dissociation of the mature GF from the pro-domain, which was immobilised on 
biosensor tips through N-terminal His-tag. We observe very slow dissociation of the GF, consistent 
with the low level of activity seen in cellular assays (Figure 2C). Interestingly, this dissociation is not 
enhanced by the natural myostatin inhibitor follistatin (FST-288, the 288 amino acid isoform). This is 
in stark contrast to the pro-activin A complex, which readily dissociates in the presence of FST-288 
(Figure 2D). On the other hand, the same experiment using uncleaved pro-myostatin shows no 
significant difference in the presence or absence of FST-288, while uncleaved pro-activin A actually 
shows an increase in response when exposed to FST-288, suggesting an interaction with the growth 
factor part of activin A, even before proteolytic cleavage releases the mature domain from its pro-
domain (Figure EV1). These results confirm that the pro-myostatin complex is highly stable, more so 
than pro-activin A. These data also suggest that regulation of myostatin by follistatin can only take 
place after the pro-domain has dissociated from the mature GF. 
Structure determination 
To elucidate the molecular determinants of pro-myostatin latency, we crystallised the unprocessed 
precursor form of human pro-myostatin, with its native furin site intact. Crystallisation of HRV-3C 
cleaved pro-myostatin was not attempted because of the low yield of homogenously processed complex. 
Unprocessed pro-myostatin crystallised readily in a number of conditions, yielding cubic crystals. These 
were used to determine the structure at a resolution of 4.2 Å, using experimentally determined phases 
from selenomethione-labelled protein (Table 1, Figure EV2). Merging data from multiple crystals 
(Appendix Table S1) significantly improved the quality of the electron density for this structure, so 
that we could trace most of the backbone and observe large side chains. However, we were unable to 
unambiguously assign the sequence of the pro-domain using this low resolution data.  
In pursuit of higher resolution, we employed the UCLA Surface Entropy Reduction prediction (SERp) 
server to identify suitable candidates for mutagenesis (Goldschmidt et al, 2007). The server returned 
three clusters of predicted surface-exposed high-entropy amino acids, two of which we confirmed to 
occupy surface positions by mapping onto our existing low-resolution structure. Residues from the first 
cluster (K217, Q218, E220) occupied positions on a poorly resolved loop extending into solvent, while 
those from the second cluster (G319, K320) were buried within a crystal contact formed by the mature 
GF domain in the original crystal form. The third cluster appeared to sit within a functional domain 
interface and so was excluded from screening. Mutagenesis (to alanine) of clusters 1 and 2 individually 
gave no crystal hits, however when both sets of mutations were combined in a single construct, the 
protein crystallised readily in a new form and diffracted to higher resolution. 
One symmetrical half of the low-resolution dimer was used as the search model for molecular 
replacement of a higher resolution dataset, and the structure was solved again, this time at 2.6 Å (Table 
1). In both crystal forms, the asymmetric unit contains a single dimeric molecule. We were able to build 
92% and 81% of residues of the two protomers into the electron density of the 2.6 Å structure. The 
remaining regions are disordered, with 27 and 62 residues missing from chains A and B respectively. 
The quality of electron density differs markedly between different parts of the two chains (Figure EV3), 
and as such, our interpretations are based on the analysis of both chains of the higher resolution 
structure.  
The structure of human pro-myostatin 
Like related pro-TGF-β superfamily members, pro-myostatin is a disulfide-linked homodimer, each 
chain of which contains an N-terminal pro-domain and a C-terminal mature GF domain (Figure 3A). 
The GF domains consist of four antiparallel β-strands or ‘fingers’ and a cystine-knot motif, 
characteristic of TGF-β superfamily members. Two identical GF protomers associate through their 
concave ‘palms’, and are linked covalently through a disulfide bond between equivalent Cys339 
residues in the GF ‘wrist’ region. The pro-domain retains the familiar structural elements of other pro-
TGF-β superfamily members, including N-terminal ‘forearm’ helices which grasp the mature GF, and 
a globular ‘arm/shoulder’ domain, which sits atop the mature GF protomers (Figure 3A). 
Given the latency of the pro-myostatin complex, it was expected that the pro-domains would adopt a 
closed conformation like that of pro-TGF-β1, albeit without the cross-linking disulfide (Shi et al, 2011). 
Instead, pro-myostatin adopts a V-shaped, “open arm” conformation with no interactions between the 
arm domains,  similar to that observed for the two non-latent complexes of pro-BMP9 and pro-activin 
A (Figure 4D) (Mi et al, 2015; Wang et al, 2016).  
The individual chains of both our low and high resolution structures overlay well (Cα RMSD: 0.68 Å, 
227 atoms, using non-covalently associated pro- and mature domains as a single entity). However, there 
is a considerable shift in the inter-protomer angle between the two structures, measured from the 
dimerization disulfide to the tips (Gln358) of the mature domain fingers, with the low resolution model 
adopting a more closed conformation (89.2° vs. 108.5°; Figure 4A). This suggests the pro-form has 
significant conformational flexibility about the dimer interface. To explore this, we used SAXS data to 
calculate a molecular envelope for uncleaved pro-myostatin. The resulting envelope shows an extended 
structure, consistent with what we see in the crystal structures, but is less well defined and multiple 
inter-protomer conformations, rotating about the dimerisation disulfide, could be accommodated within 
the envelope (Figure 4B).  
The individual mature GF protomers also overlay well with the structure of myostatin bound to 
follistatin 288 (PDB: 3HH2, C RMSD: 0.63Å, 65 atoms), but exhibit a shift in inter-protomer angle 
(Figure 4C)(Cash et al, 2009). This observation is consistent with that of Walker et al, who recently 
showed that the mature myostatin GF dimer crystallises with radically different inter-protomer angles 
in apo and FST-288 bound states (Figure 4C) (Walker et al, 2017a). Conformational plasticity is 
similarly well documented for activin A, which has inter-protomer angles ranging from 50° in complex 
with type II receptor ecto-domain (PDB: 1NYS), to 108° when bound to FST-315 (PDB: 2P6A) (Wang 
et al, 2016).  
In both of our structures, the GF domain ‘wrist’ helix and pre-helix region, which forms a significant 
interface with the opposing protomer, and establishes the presumed binding site for the type I receptor, 
is displaced in the presence of the pro-domain. Instead, this sequence forms a β–hairpin visible within 
the crystal contact of one chain and binds on the exposed face of the pro-domain α1 helix (Figure 3A). 
The GF wrist helix and pre-helix region are thought to constitute an important component of the putative 
type I receptor epitope and while there is currently no structure of a myostatin-receptor complex, the 
ALK5 binding mode can be inferred from the ALK5:TGF-β3 structure (2PJY) (Groppe et al, 2008). 
Displacement of the wrist helix by the pro-domain would render myostatin unable to engage the type I 
receptor while bound to its pro-domain. In contrast to this, the N-terminal domain (ND) of FST-288 
occupies the type I receptor site without displacing the wrist helix, and this site is known to 
accommodate a number of different ligands by utilising this ‘non-invasive’ binding mode (Cash et al, 
2009). In pro-TGF-β1 the wrist helix is also displaced, and in pro-activin A density for the helix is 
missing altogether, suggesting similar displacement from the core of the GF domain (Shi et al, 2011; 
Wang et al, 2016). In the pro-BMP9 structure, the wrist helix remains in place, with the α5 helix from 
the prodomain occupying a similar position to the helix of the FST-288 ND domain (Mi et al, 2015).  
Pro-myostatin forms a domain-swapped, open armed dimer 
Similar to previously determined structures of TGF-β family pro-domains, the myostatin pro-domain 
consists of an N-terminal α1 helix/loop/α2 helix ‘forearm’ motif, and a C-terminal globular ‘arm’ 
domain (Figure 3A) (Shi et al, 2011). The pro-myostatin forearm is structurally similar to that of pro-
TGF-β1 and pro-activin A, with the exception of a five residue insert, which forms a short α-helix (lasso 
helix) in the latency lasso linking α1 and α2 helices. The α1 helix of the myostatin pro-domain occupies 
the hydrophobic groove on the concave surface of the GF protomer fingers, effectively blocking the 
putative type I receptor binding site. The α1 helix is followed by the latency lasso which wraps between 
the ‘fingertips’ of the GF domain, providing an interface between pro and GF domains. The downstream 
α2 helix extends across the convex surface of one GF protomer, and occludes the type II receptor 
binding site (Figure 3A).  
Electron density for the sequence linking the pro-domain forearm to the arm domain, and housing the 
TLD cleavage site (Arg98/Asp99), is missing in both protomers. Based on the distances between 
resolved residues and the directionality of electron density, it is apparent that the connectivity from the 
pro-domain forearm to the arm is such that the forearm interacts with the GF domain from the same 
chain, but with the arm from the opposite chain, giving rise to a domain-swapped arrangement, as is the 
case for pro-activin A (Figure 3B) (Wang et al, 2016). The distance from the last resolved residue of 
the forearm (Asp95) to the first visible residue of the arm (Glu107) is 22.7Å in our proposed domain-
swapped arrangement (Figure EV4). In the alternative connectivity, the missing 11 residues must span 
35.2Å, which would require a near linear trajectory between endpoints. Such a constrained structural 
feature is unlikely given the lack of electron density in this region. With the domain-swapped topology, 
the extent to which the V-shaped dimer can open up will be limited by the linker sequence between α2-
helix and the arm domain binding to the opposite mature domain. Our high resolution structure is 
missing 11 and 12 residues from this linker in the two protomers and the last visible residues are 23 and 
24 Å apart, respectively, suggesting that a more open conformation could be still be accommodated 
(Figure EV4).  
Similarly, density for the furin cleavage site and sequence linking the pro-domain to the GF domain is 
weak and missing in places, however we were able to trace the entire main-chain connecting the pro- 
and mature domains in one of the two protomers. The density supports an additional domain-swapped 
conformation in which the pro-domain arm of one chain interacts with the GF domain of the other 
(Figure EV4). It is noteworthy that the furin site is visible in our structure, as it suggests that pro-
myostatin is a more constrained substrate for furin than pro-TGF-β1 and pro-activin A, which both lack 
density for the furin site. The uncleaved pro-activin A structure is missing ten residues with 16 Å 
between the last visible residues, whereas in pro-myostatin 12 residues span a direct distance of 34 Å 
resulting in a less flexible and therefore less accessible furin cleavage site (Figure EV4).  
Given the unusual open-armed conformation and lack of interaction between pro-domain arms, the 
question arises as to what drives the increased latency of the pro-myostatin complex over non-latent 
superfamily members. 
Latency conferring interactions of the pro-domain forearm 
One of the key latency determining regions of the TGF-β superfamily pro-domains is the N-terminal 
helix-loop-helix forearm motif, with residues 42-115 originally identified as the inhibitory fragment of 
pro-myostatin (Jiang et al, 2004). This range incorporates the entire forearm region, extending from the 
N-terminus of the α1 helix to the start of the arm domain, and many of these latency conferring 
interactions are conserved between pro-myostatin and pro-TGF-β1 (Shi et al, 2011). In our structures, 
the α1 helix is clearly helical in nature from Arg45 to Leu64. As anticipated, the pro-domain α1 helix 
interaction with the GF domain is dominated by hydrophobic interactions, and of the seven aliphatic 
residues within this helical sequence, six are buried within the hydrophobic groove of the GF domain 
(Figure 5A). These aliphatic residues are conserved in pro-TGF-β1 (with exception of Ile58), and are 
known to contribute towards its latency (Figure 5F) (Walton et al, 2010). Takayama et al. have 
synthesised a range of myostatin inhibitory peptides based on the mouse pro-domain α1 helix sequence, 
the best of which (Trp44-Leu64) binds to mature myostatin with a KD of 29 nM and has been shown to 
increase muscle mass in mouse models of muscular dystrophy (Takayama et al, 2015). The same 
authors have shown by alanine scanning that the aforementioned hydrophobic residues are critical to 
the inhibitory function of these peptides (Asari et al, 2016). Nevertheless, the affinities of these α1 
helix-derived peptides are not high enough to fully explain the latency, in line with the fact that many 
of these residues are conserved in non-latent pro-activin A (Figure 5F). 
In addition to hydrophobic contributions, a number of electrostatic interactions appear to stabilise the 
α1 helix:GF interface. Arg45 (conserved in pro-GDF11 but not in other family members), forms 
hydrogen bonds with backbone carbonyls of Glu274 and Ser276 located on the N-terminal extension 
of the GF domain (Figure 5B), but truncation of the arginine sidechain has been reported to have little 
effect on the inhibitory function of α1 helix derived peptides (Asari et al, 2016). Lys49 forms a salt 
bridge with the side chain of Glu274 while Arg52 forms multiple hydrogen bonds to backbone 
carbonyls of Ala306, Asn307 and Met367 from the GF fingers, and Lys63 near the C-terminus of the 
α1 helix hydrogen H-bonds to the main-chain carbonyl of Pro365.  
Cationic residues within the α1 helix of pro-TGF-β1 are reported to mediate non-covalent interaction 
with ECM bound LTBP-1, promoting subsequent covalent linkage through Cys33 (Walton et al, 2010). 
Given the conservation of these residues in pro-myostatin, and the prior observation that pro-myostatin 
interacts non-covalently with LTBP-3 (the primary LTBP expressed in skeletal muscle), it is possible 
that these interactions are conserved (Anderson et al, 2008). From a structural perspective, these 
charged residues may maintain the complex in a conformation that is competent for LTBP association 
(Arg52 and Lys63 are buried in the α1:GF interface), or form part of the LTBP-3 docking site (Lys57 
is exposed to solvent and thus a potential LTBP-3 binding candidate). 
The latency lasso extending from the C-terminus of the α1 helix wraps around the mature domain 
fingertips. A five amino-acid insertion in the latency lasso, unique to pro-myostatin and pro-GDF11, 
creates a short ‘lasso helix’ not observed in other pro-TGF-β family structures (Figure 5A). The 
downstream α2 helix lies against the convex face of the GF, occluding the putative type II receptor site. 
Tyr94 of the α2 helix forms a hydrogen bond to the Asn349 backbone carbonyl, an interaction also 
observed in pro-TGF-β1 (Figure 5E). The forearm:GF interface is dominated by aliphatic residues, and 
the shielding of these hydrophobic surfaces by the pro-domain is consistent with the vastly increased 
solubility of the pro-forms over the mature ligands, which are notoriously prone to aggregation under 
physiological-like buffer conditions. 
The pro-domain arm forms an extensive stabilising interface 
The globular arm domain of pro-myostatin is structurally conserved with other pro-TGF-β superfamily 
structures and consists of two anti-parallel β-sheets and a short α-helix. Unlike pro-TGF-β1, the pro-
myostatin arm domain lacks the β8/9 hairpin extension which facilitates covalent dimerization of the 
pro-TGF-β1 pro-domains (Shi et al, 2011). 
One of the distinguishing features of pro-myostatin is the substantial interface that the globular arm 
domain shares with the GF/forearm. The arm adopts a markedly different conformation to that of pro-
activin A and pro-TGF-β1. Given the lack of a covalent constraint (as in pro-TGF-β1), the pro-
myostatin arm is rotated almost ‘parallel’ to the mature domain, forms an extended β-sheet with the GF 
domain and creates a considerably larger interface with the GF and forearm helices (Figure 6A). This 
results in extended hydrogen bonding at the antiparallel β-sheet interface between GF β7’ strand and 
arm domain β1 strand, with eight hydrogen bonds, compared to five in pro-Activin A, four in pro-
BMP9, and only two for pro-TGF-β1 (Figure 6B). Given the high degree of conservation between pro-
myostatin and pro-GDF11 at this interface, it is likely that pro-GDF11 forms a similarly extensive 
stabilising hydrogen bonding network. In the case of pro-TGF-β1, the reduced β-sheet interface is the 
result of considerable twisting between mature and arm domains to accommodate its ‘closed’ 
conformation.  
The pro-myostatin arm straddles the GF, and interacts with the forearm on both convex and concave 
sides of the GF, effectively sandwiching it between (Figure 6A). The β6/β7 loop of the arm domain 
latches over the latency lasso, completing the circle of pro-domain elements which enclose the second 
finger of the GF creating a straightjacket-like structure around it (Figure 6C). This extensive interaction 
may function to both mask surface hydrophobicity, and stabilise the furin cleaved complex, preventing 
spontaneous activation by dissociation. Furthermore, there is a well resolved stacking interaction 
between Arg65 at the tip of the α1 helix, with Tyr111 and His112 from the linker containing the TLD 
cleavage site, which appears to hold this cluster of charged features close to the α1 helix, further 
stabilising the arm/latency lasso interface (Figures 5C, 5D, 6C). These residues are equivalent to the 
‘fastener’ residues described for pro-TGF-β1, non-conserved mutation of which was shown to liberate 
TGF-β1 signalling (Shi et al, 2011). Paired aromatic residues capable of forming stacking interactions 
are conserved in this position in all three TGF-β isoforms and in GDF11, and are likely to be important 
contributors to the latency of these pro-complexes. 
It is interesting to note that the highly acidic sequence downstream of the TLD cleavage site (Glu107, 
Asp108, Asp109, Asp110) and the highly basic furin cleavage site (Arg263, Ser264, Arg265, Arg266) 
from the same chain almost overlap within the cavity between protomers (Figure 5C). It is tempting to 
speculate that interaction between the primary and secondary cleavage sites may play a role in the 
regulation of pro-myostatin activation. In the domain-swapped arrangement, in which the same chain 
crosses first from the N-terminal forearm to the arm domain on the opposite side and then back again 
to the mature GF, the entire complex is supported by criss-cross connectivity with the furin site coming 
over the TLD site, possibly providing steric protection of the latter. Cleaving the furin site would release 
the first of these tethers, potentially increasing lability of the pro-domain arms. For activin A, furin 
cleavage seems to be sufficient to release the latency that the pro-domain exerts, whereas in the case of 
myostatin, the arm domain interaction is strong enough to prevent dissociation from the mature growth 
factor, stabilised by the link from α2 helix to the first β-strand of the pro-domain. Subsequent cleavage 
of the TLD site removes this second tether, possibly disengaging the fastener interactions and allowing 
the arm, which is now attached only non-covalently, to dissociate from the GF/Forearm. Given that 
myostatin can be secreted as the unprocessed precursor, there is a possibility that TLD cleavage could 
occur before furin cleavage, however to the best of our knowledge there is no data showing that TLD 
cleavage alone is sufficient for activation. It therefore remains to be seen whether the order of furin and 
TLD cleavages can vary and whether this would affect the efficiency of myostatin activation in the 
extracellular matrix.   
Structural polymorphisms in human pro-myostatin 
So far 134 unique naturally occurring missense mutations, involving 112 residues (77 in the pro-
domain), have been identified in human pro-myostatin (Ensembl genome assembly GRCh38.p10, 
accessed on 05.06.2017, see Appendix Table S2). In order to further probe the molecular determinants 
of latency, a series of pro-myostatin variants were made, designed either to recapitulate interesting 
natural polymorphisms, or to disrupt previously unappreciated interactions that we identified by 
structural analysis (Takayama et al, 2015; Asari et al, 2016). The most interesting substitutions for this 
analyses were those affecting the fastener (Arg65Ala, Arg65Cys, Tyr111His, His112Arg), and 
Lys153Arg, which has been associated with muscle and obesity related phenotypes (Garatachea et al, 
2013; Santiago et al, 2011; González-Freire et al, 2010; Bhatt et al, 2012; Szláma et al, 2015). In 
addition, we chose to analyse a naturally occuring Ala84Gly variant at the interface of forearm and arm 
domains as well as Trp203 which forms part of the globular arm domain, and makes a hydrogen bond 
with backbone of Lys83 in the latency lasso via the tryptophan indole nitrogen. Trp203 was mutated to 
Ala, His and Phe, in an attempt to minimise the effect of removal of the large side chain from the core 
of the arm. All mutated residues and their immediate surroundings are shown in Figure 7A. In addition 
to the structural polymorphisms described here, Walker & McCoy et al provide a robust mutagenesis 
study of pro-myostatin residues predicted to contribute to latency, by modelling pro-myostatin on the 
latent pro-TGF-β1 structure (Walker et al, 2017b). That work was extended here based on the analysis 
of our experimental pro-myostatin structure. 
We first created expression constructs of selected mutants for production in HEK293-(CAGA)12 
luciferase reporter cells, to analyse the effect of these mutations on bioactivity. In this setup, secreted 
pro-myostatin complexes showed minimal activity in the absence of cleavage at the tolloid-site, 
however when proteins were produced by co-transfecting cells with increased amounts of a construct 
encoding human tolloid-like 2, a number of variants showed deviation from wild-type activity levels 
(Figures 7B, Appendix Figure S2). Mutation of Arg65 from the fastener motif to alanine increased 
signalling activity significantly over the wild type, but mutation of the same residue to cysteine caused 
a reduction in activity, presumably because of the detrimental effect of introducing a lone cysteine into 
an extracellular protein. The other fastener polymorphisms also increased myostatin activation with 
His112Arg behaving similarly to Arg65Ala, but Tyr111His was the most effective in reducing the 
latency of the protein, with over 2-fold higher activity compared to the wild type protein. Walker & 
McCoy et al similarly show that disruption of the fastener interaction (with Y111A, and H112A 
mutations) enhances activation of pro-myostatin over the wild-type (Walker et al, 2017b). The 
mechanism of increased activity of these variants is not certain, however it seems likely that weakening 
of the fastener interaction promotes increased dissociation of the pro-domain fragments following 
proteolysis by furin and TLD sites. It is possible that introduction of certain polymorphisms may 
influence the efficiency of proteolytic processing of pro-myostatin. The fastener motif pulls together 
the flexible linkers with furin and tolloid sites and, speculatively, disruption of fastener residues may 
grant the cleavage sites additional conformational flexibility and proteolytic lability. This is supported 
by the observation that the fastener mutants show proportionally higher increase in bioactivity 
compared to the other mutants when the amount of co-expressed hTLL-2 is increased. (Appendix Figure 
S2). 
Somewhat surprisingly, the known polymorphic variant Lys153Arg had only a modest effect on 
myostatin activity, compared to wild-type protein (González-Freire et al, 2010). The Ala84Gly variant 
showed no effect over the wild type protein. Mutations of Trp203 showed minimal increase in activity 
with low levels of tolloid co-expression, but at higher tolloid concentrations (where the wild-type 
protein was ca. 6x more active), Trp203 variants showed significantly reduced activity. This may be 
due to disruption of protein stability and/or folding and secretion, given that Trp203 is involved in a 
tightly packed hydrophobic interaction within the pro-domain arm. 
To analyse the effect of these mutations in more detail, the same mutations were introduced into an E. 
coli expression construct of the myostatin pro-domain. The pro-domains (residues 24-262) were 
expressed solubly in E. coli as MBP fusions and assessed for their ability to inhibit mature myostatin in 
trans. Mutations of Trp203 and the Arg65Cys mutant gave very poorly soluble protein and thus were 
excluded from this part of the study. The wild-type myostatin pro-domain inhibited mature myostatin 
signalling in our experimental system, with an IC50 of 0.9 nM (95% C.I [0.83 – 1.08]) (Figure 7C). All 
variant forms of the pro-domain inhibited signalling with a similar range as the wild-type (Figure 7C, 
Appendix Table S3). The fact that these pro-domain variants did not recapitulate the same pattern of 
effects on activity observed for HEK293 expressed pro-complexes suggests these mutations do not 
meaningfully disrupt the pro:mature complex when reconstituted in trans. This may point to a 
mechanism in which the latency driving interactions are fully established only when the native protein 
folds and assembles into the domain-swapped complex. It is possible that when supplied in trans, the 
purified pro-domains fail to reach conformational equilibrium with those of the endogenously produced 
pro-complex and thus any polymorphism derived variation in potency remains unresolved. 
Alternatively, the introduction of mutations could affect the efficiency of proteolytic processing, 
without significantly impacting the latency of the cleaved complex.  
DISCUSSION 
Extracellular regulation of cell-signalling proteins is of clear biological importance, both during 
development and into maturity. Storage of signalling molecules in the extracellular matrix provides a 
means of rapid response to physiological change, avoiding the need to first synthesise, process and 
secrete the protein following stimulation. The mechanisms of extracellular storage and regulation of 
TGF-β family growth factors are diverse and a spectrum of latency exists within the pro-TGF-β 
superfamily, ranging from the fully auto-inhibited TGF-βs, to the BMPs and activins which readily 
dissociate from their pro-domains following cleavage, and instead rely on soluble antagonists to 
regulate signalling (Yanagita, 2005). Pro-myostatin occupies an intermediate position on this scale, 
forming a weakly bioactive complex which requires further proteolytic activation to liberate its full 
signalling capacity (Szláma et al, 2013).  
The pro-domains of TGF-β superfamily proteins are poorly conserved in sequence with comparison to 
the mature GF domains, making structural predictions and modelling of the pro-domains difficult 
(Hinck et al, 2016). In addition to variation at the amino-acid sequence level, the pro-forms for which 
we have structural information, show marked variability in their overall domain topology. The 
structures solved here show that latent pro-myostatin does not conform to the expectation of a ‘closed-
arm’ conformation, as is seen for latent pro-TGF-β1. Instead, pro-myostatin forms an open, elongated 
structure, more reminiscent of non-latent pro-Activin A and pro-BMP9. The open-armed conformation 
observed crystallographically (in two distinct crystal forms) also exists in solution, as shown by SAXS, 
and interestingly, the overall conformation (and associated particle dimensions) does not seem to 
change significantly upon cleavage of the pro-domain. These findings are corroborated further by Le et 
al, who were able to clearly resolve the distinctive V-shape of pro-myostatin (and the furin cleaved 
complex), using negative stain electron microscopy (EM) (Le et al, 2017).  
Despite differing overall topologies, the specific pro:GF interactions which drive the latency of these 
pro-complexes are mostly conserved with pro-TGF-β1, with the exception of the covalent linkage of 
TGF-β1 pro-domains at the bow-tie motif. In the absence of the avidity provided by the pro-domain 
dimerization, myostatin utilises other mechanisms to increase its latency compared to activin A, which 
in its overall topology is much more similar to myostatin. Our analyses suggest that there is no single 
critical feature that confers latency to the protein, but rather the latency arises from multiple features 
that increase the pro-mature affinity combinatorially. The latency conferring features identified for pro-
myostatin are conserved within the sequence of pro-GDF11 and as a result, we predict it will have a 
highly similar overall structure. This prediction is supported by the work of Pepinsky et al who recently 
demonstrated by negative-stain electron microscopy that latent pro-GDF11 adopts a V-shaped topology, 
very similar to that of our pro-myostatin structures and consistent with the EM analysis of pro-myostatin 
by Le et al (Le et al, 2017; Pepinsky et al, 2017).  
We propose a model for the synthesis and activation of myostatin, based on the structures and data 
presented here and in other studies (Figure 8). With the domain-swapped, criss-crossed conformation 
of the protomer of pro-myostatin dimer, it is likely that a monomeric structure forms first, with the pro-
domain supporting a dimerization-compatible conformation of the mature domain (Figure 8A-C). In 
this dimeric unprocessed precursor form of myostatin we can identify a number of features that 
contribute to its latency and provide a foundation for a tightly controlled activation process. The key 
features are: increased affinity of the α1 helix for the mature GF, a fastener epitope that locks the N-
terminus around the mature GF domain fingers and the extended interface that the pro-domain arm 
makes with the mature GF and the latency lasso that binds to it, stabilising this complex (Figure 8D). 
This latency is released by a controlled, sequential proteolysis of the furin and TLD sites, with the furin 
site in particular being only moderately accessible and, at least before cleavage, partially obscuring the 
tolloid site (Figure 8E-F). Cleavage of the furin site alone is not sufficient for full activation, as the 
extended non-covalent interactions prevent the furin-cleaved complex from dissociating, even in the 
presence of competing high affinity antagonist follistatin. Release of the second TLD tether and 
separation of the two halves of the pro-domain is required before myostatin can exert its function. The 
arm domain is free to dissociate once the covalent linkage to the forearms is severed, which would then 
allow the helix-loop-helix epitope to dissociate as well (Figure 8G-H). Increased rates of 
hydrogen/deuterium exchange at pro:mature interaction sites following TLD cleavage as shown by Le 
et al, demonstrates increased lability of the shouder and forearm following TLD cleavage, priming the 
complex for dissociation (Le et al, 2017). Analysis of closely related GDF11 has shown that the N-
terminal part of the pro-domain, with 1 and 2 helices can remain associated with the mature GF, 
promoting its solublity while not affecting bioactivity, consistent with a stepwise dissociation model 
(Pepinsky et al, 2017). Finally, dissociation of the α1 helix will enable the GF wrist-helix to form, re-
establishing the type I receptor binding site (Figure 8I). The mature GF is now free to interact with its 
receptors and induce signalling. At the same time, this mature GF becomes a target for soluble inhibitors 
such as follistatin, which must act before the mature GF finds its receptor on cell surface.  
It is possible that the fully latent complex can only assemble during synthesis, as supported by our 
mutagenesis data in which pro-domain variants which reduce latency of the pre-assembled complex do 
not have the same effect when the variant pro-domain is supplied in trans. This is consistent with the 
data of Walker et al, who show that the pro-myostatin complex reconstituted from its individually 
purified components has reduced latency compared to the natively expressed complex (Walker et al, 
2017b). While our latent pro-myostatin complex shows low-level signalling activity in cellular assays, 
it is likely that the cleaved pro-complex is further stabilised in vivo, by interactions with components of 
the extracellular matrix, including perlecan and LTBP-3, which are known to bind elements of the pro-
myostatin pro-domain (Anderson et al, 2008; Sengle et al, 2011). Non-covalent bridging of pro-
domains by ECM bound interactors could provide a mechanism for increasing functional affinity of the 
complex.  
This structure and the analysis of the activation process provides us with a framework for assessing the 
effect of polymorphisms on myostatin function. Analyses of several missense polymorphisms in the 
pro-domain of myostatin demonstrate that some of these variants are more easily activated, and could 
potentially affect the musculature of those carrying the polymorphisms. As most of these polymorphism 
data are part of large scale anonymised studies, we are unable to correlate our results with phenotypic 
information relating to these individuals.  
In addition to furthering our understanding of the molecular details of pro-myostatin activation, the 
structural insight gained here should aid in the development of more effective next generation myostatin 
inhibitors. To date, a number of myostatin-neutralising therapies have entered clinical trials for 
treatment of various muscle wasting conditions, but most fail to meet efficacy and safety standards. An 
emerging alternative strategy for pharmacological blockade of myostatin signalling is to target the latent 
precursor forms rather than the short-lived mature ligand. One could effectively suppress myostatin 
signalling by stabilising the latent pro-forms, either by preventing the dissociation of the pro-complex 
or by inhibiting proteolytic processing of the precursor. Targeting the less-conserved pro-domain should 
also enable development of more specific therapeutic agents compared to those aimed at the conserved 
GF domain. The high resolution structure of pro-myostatin presented here will be a valuable resource 
for future efforts in developing effective therapeutics for the treatment of muscle-related pathologies. 
METHODS 
Cloning and expression of pro-myostatin constructs for bacterial expression 
A construct encoding human pro-myostatin lacking the signal peptide (residues 19-375, Uniprot 
014793) was cloned into pHAT2 vector using BamHI and NotI restriction sites (pro-MSTN). The final 
construct contained an N-terminal His-tag and additional linker sequence, appending a total of 20 non-
native amino acids to the protein N-terminus. For crystallography constructs, a TEV cleavage site was 
introduced into the N-terminal sequence by substituting the native sequence from Glu36-Cys42 with 
the TEV consensus ENLYFQGS, allowing removal of the predicted disordered N-terminus (proMSTN-
Δ43) in-vitro (Ward et al, 2004). Surface entropy reduction mutations, identified using the UCLA SERp 
server (Goldschmidt et al, 2007) (G319A, K320A, K217A, Q218A, E220A), were introduced into the 
Δ43 crystallography construct (proMSTN-Δ43-mut).  
For functional experiments, an additional construct was generated in which an HRV-3C protease site 
was engineered into the position of the native furin cleavage site, to allow robust cleavage in-vitro 
(proMSTN-3C). The aforementioned modifications to the original construct were completed using 
multi-step PCR protocol with overlapping oligonucleotide primers containing the modified sequence. 
The sequences of all oligonucleotides used for cloning are listed in Appendix Table S4. 
Sequence-verified constructs were transformed into competent BL21(DE3)+pUBS520 cells by heat-
shock and then grown overnight at 37°C overnight on LB-agar plates supplemented with 100 μg/ml of 
ampicillin and 25 μg/ml kanamycin. The cells were grown in 1L 2xYT media until OD600 between 0.8-
1.0 and then for an additional 3 hours at 37°C after induction with 400 μM IPTG. The resulting cell 
pellet was harvested by centrifugation (4000 g, 20 mins). 
Refolding and purification of bacterially expressed pro-myostatin constructs  
E. coli cells were lysed with Emulsiflex C5 and inclusion bodies prepared as per Wang et al, 2016 
(Wang et al, 2016). The washed inclusion bodies, from 1L culture volume, were resuspended in 100 
mM TCEP pH 7.0 and then solubilised by addition of 15 mL solubilisation buffer (8 M guanidine-HCl, 
50 mM Tris-HCl pH 8.0, 10 mM EDTA and 0.1 M cystine) and incubated at room temperature while 
shaking, for 1 hour. The solubilised protein was clarified by centrifugation (15,000 g, 20 mins) and 
soluble material buffer exchanged into 6 M urea and 20 mM HCl, adjusted to 1 mg/mL and rapidly 
diluted 1:10 into 1L of cold refolding solution (100 mM Tris-HCl pH 9.0, 1 M pyridinium propyl 
sulfobetaine (PPS), 0.5 mM EDTA, 0.2 mM cystine and 2 mM cysteine) while stirring vigorously. The 
refolding solution was kept at 4°C for 7 days before purification.  
One litre of refolding solution was filtered (0.65 µM Sartopure filter cartridge) prior to loading onto a 
10 mL Source Q15 anion exchange column (GE Healthcare)  pre-equilibrated with 50 mM Tris-HCl 
pH 9.0. Five column volumes of the equilibration buffer were used to wash the unbound material, 
followed by elution with a linear gradient over 20 column volumes from 0-100% elution buffer (50 mM 
Tris-HCl pH 9.0, 1 M NaCl). For crystallographic constructs, the His-tagged N-terminus was removed 
by TEV protease cleavage. Following anion exchange capture, the pooled fractions were buffer 
exchanged to 20 mM Tris pH 8.0, 150 mM NaCl and incubated overnight with 200 µL TEV protease 
(2 mg/mL). TEV cleaved pro-myostatin was incubated with PureCube Ni-NTA agarose (Cube Biotech, 
Germany) to separate the cleaved N-terminus and protease. After incubation with Ni-NTA resin for one 
hour at 4°C, the flow through containing cleaved protein was collected. 
As a final step of purification for all constructs, protein fractions were concentrated and loaded onto 
HiLoad Superdex 200 16/60 gel filtration column (GE Healthcare) pre-equilibrated with 20 mM Tris 
pH 8.0, 150 mM NaCl. Peak fractions were pooled and analysed by reduced and non-reduced SDS-
PAGE. 
Selenomethionine-labelled protein was expressed in minimal medium using metabolic suppression 
method to minimise endogenous methionine production and refolded and purified like the unlabelled 
protein. Selenomethionine incorporation was confirmed to be complete by mass spectrometry. 
For production of the cleaved pro-myostatin complex, the native furin site was replaced by an HRV-3C 
cleavage site, and the protein purified as described for the wild-type protein, except for initial capture 
from refolding which was done using 5mL HiTrap Q HP (GE Healthcare) column instead of Source 
Q15 column. The purified protein was then incubated with GST-HRV 3C fusion at a 4:1 mass ratio for 
3 days at 4°C in gel filtration buffer (above). GST-tagged HRV 3C was separated from the cleaved 
complex by incubation with PureCube glutathione agarose resin (Cube Biotech, Germany). The 
complex was further purified by gel filtration (as above) with the dimeric mature domain and prodomain 
co-eluting as a single peak suggesting successful formation of a stable complex.  
Mature myostatin was purified from the HRV-3C cleaved pro-myostatin complex by reverse phase 
chromatography (RPC). Acetonitrile and trifluoroacetic acid (TFA) were added to the purified complex, 
for final concentrations of 10% and 0.1% respectively. The acidified complex was then loaded onto 
ACE C8 300 4.6x250 mm RPC column, pre-equilibrated with 10% ACN and 0.1% TFA. The protein 
was eluted over 20 column volumes to 100% elution buffer (90% ACN, 0.1% TFA). Peak fractions 
were then dried by centrifugal evaporation. Mature myostatin was resuspended in 10 mM HCl prior to 
use. All protein concentrations were determined spectrophotometrically using calculated absorption 
coefficients at 280 nm.  
Bacterial expression and purification of wild-type and variant pro-domains 
A cDNA fragment encoding the wild-type human pro-domain (residues 24-262, Uniprot 014793) was 
cloned into pET28a vector containing N-terminal 6x His tag and MBP fusion. To improve solubility 
and stability, the four pro-domain cysteines were mutated to serine and MBP was modified for surface 
entropy reduction according to Moon et al, 2010 (Moon et al, 2010). Specific polymorphisms were 
introduced into the pro-domain sequence using QuickChange PCR protocol with PfuUltra II Fusion HS 
DNA polymerase (600670, Agilent Technologies).  
MBP-prodomain fusion constructs were transformed into competent Rosetta(DE3)pLacI cells by heat-
shock and then grown overnight at 37°C overnight on LB-agar plates supplemented with 34 μg/ml of 
chloramphenicol and 25 μg/ml kanamycin. The cells were grown in 1L 2xYT media until OD600 0.6-
0.8 and then overnight at 18°C after induction with 400 μM IPTG. The resulting cell pellet was 
harvested by centrifugation (4000 g, 20 mins) and resuspended in lysis buffer (20 mM Tris pH 8.0, 500 
mM NaCl, 10 mM imidazole) supplemented with protease inhibitor (cOmplete Mini, EDTA-free, 
Roche). Following lysis with Emusiflex C5, lysate was clarified by centrifugation (15,000 g, 20 mins), 
filtered and incubated with 1 mL PureCube Ni-NTA agarose for 1 hour at 4°C. The resin was washed 
with 5x 5mL volumes of wash buffer (20 mM Tris pH 8.0, 500 mM NaCl, 20 mM imidazole) and eluted 
in 0.5 mL fractions with elution buffer (20 mM Tris pH 8.0, 500 mM NaCl, 500 mM imidazole). Ni-
NTA affinity purified His-MBP-pro-domain fusions were concentrated and loaded onto HiLoad 
Superdex 200 16/60 gel filtration column pre-equilibrated with 20 mM Tris pH 8.0, 500 mM NaCl. 
Peak fractions were pooled and analysed by SDS-PAGE (Appendix Figure S3). 
Crystallisation and data collection 
Purified unprocessed pro-myostatin crystallisation constructs were concentrated to 10 mg/mL and 
screened for crystallisation in commercial 96-well screens (Qiagen, Molecular Dimensions, Rigaku 
reagents, USA). Sitting drops containing 300 nL protein solution and 150 nL reservoir were dispensed 
using Mosquito crystallisation robot (TTP Labtech), and incubated at 19°C. Subsequent optimisation 
screens were prepared in 96-well format using Dragonfly robotics (TTP Labtech), and sitting drops 
prepared as above.  
Wild-type human pro-myostatin with N terminal truncation (proMSTN-Δ43), gave large (100-200 µm) 
cubic crystals in 0.1 M Na acetate (pH 4.2) with 1 M ammonium phosphate, reaching maximum size 
after one week. The subsequently engineered construct bearing the N-terminal truncation and combined 
surface mutations G319A, K320A, K217A, Q218A, E220A (proMSTNΔ43-mut) gave diffraction 
quality crystals overnight in 10% PEG 6K, 0.1 M HEPES pH 7.0. All crystals were flash frozen after 
transfer to a drop of mother liquor containing 26 % ethylene glycol. 
Structure determination 
Diffraction data from cryo-cooled crystals were collected at Diamond Light Source on beamline I-03. 
For the SAD phasing of the SeMet-labelled proMSTN-Δ43, data were collected at the Se-peak 
wavelength (0.97970 Å) from multiple crystals, which had been grown under identical conditions. All 
data were processed using autoPROC (XDS, Pointless, Aimless, CCP4 suite) and the 7 highest quality 
datasets chosen for merging (Appendix Table S1) (Vonrhein et al, 2011; Kabsch, 2010; Evans, 2006; 
Evans & Murshudov, 2013; Winn et al, 2011). Their quality and mutual compatibility were assessed 
with regards to to diffraction quality, similarity of unit cell dimensions, resulting Rmerge and quality of 
the anomalous signal. These datasets were merged using autoPROC/Aimless with a resolution cutoff 
of 4.19 Å; SAD phasing was performed using Phenix (AutoSol) (Adams et al, 2010; Terwilliger et al, 
2009). The atomic model was built using Coot and the structure refined using phenix.refine and 
autoBUSTER (Bricogne et al, 2016).  
To determine the high-resolution structure of proMSTNΔ43-mut, data from a single crystal were 
processed using autoPROC to 2.59 Å. A partially refined low resolution model of proMSTN-Δ43 was 
used as a molecular replacement search model in PHASER, and model building and refinement were 
performed as above (McCoy et al, 2007).  
Statistics of data collection, processing and refinement are shown in Table 1. Both the low and high 
resolution structures and their corresponding structure factors have been deposited in the Protein Data 
Bank (http://www.wwpdb.org/) with accession codes 5NXS and 5NTU, respectively. All structural 
figures were prepared using PyMol (Version 1.8 Schrödinger, LLC).  
SAXS data collection and analysis 
Small angle X-ray scattering (SAXS) data were collected at the Soleil synchrotron SWING beamline 
(Gif-sur-Yvette, France) using a SEC-SAXS setup. The sample–detector distance was 1784 mm, 
providing a q range of 0.006–0.613Å−1 using a PCCD170170 (AVIEX) detector.  
Samples (40 µL at a concentration of 7.5 mg/mL and 20 µL at 9 mg/mL for unprocessed pro-myostatin 
and cleaved pro-myostatin complex, respectively) were injected at 0.075 mL/min into a size-exclusion 
chromatography column (GE Superdex 200 Increase 10/300), pre-equilibrated with 20 mM Tris (pH 
8.0) and 150 mM NaCl, in line with a quartz  flow cell. Sample temperature was maintained at 293 K 
during data collection. 250 frames of scattering data were collected at an energy of 12000 eV during 
elution of each sample, with 0.75 s frame duration and 0.25 s dead time in between frames. In-house 
synchrotron software (FOXTROT 3.4.1) was used to select and average frames across elution peaks 
based on their Rg values and to subtract buffer scattering obtained from SEC flow-through data. 
SCATTER 3.0 was used to plot scattered intensity (I) versus q for analysis of the forward scattering 
I(0) and radius of gyration (Rg) from the Guinier approximation (Rambo). Guinier plots were linear 
for qRg< 1.3, suggesting samples were free of aggregation. DATGNOM (ATSAS package, EMBL) was 
used to calculate the pair-distance distribution function P(r), for estimation of maximum particle size 
(Dmax), based on truncated data-sets with q-ranges of 0.0063-0.2046 (unprocessed pro-myostatin) and 
0.0114-0.2046 (cleaved pro-myostatin complex) (Petoukhov et al, 2012).  
The ab initio modelling software DAMMIN (ATSAS, EMBL) was used to generate a molecular 
envelope of uncleaved pro-myostatin precursor. 34 independent ab initio models were generated, 
assuming P2 symmetry, averaged using DAMAVER (ATSAS, EMBL) and filtered by DAMFILT 
(ATSAS, EMBL) to give a final model. The crystal structure of unprocessed pro-myostatin (PDB code: 
5NTU) was docked into the envelope with SUPCOMB (ATSAS, EMBL) and visualised using PyMOL. 
Luciferase assay 
In order to assess the signalling activity of purified pro and mature forms of myostatin, a dual-luciferase 
reporter assay using transiently transfected HEK293T cells (ATCC, catalogue no. CRL-3216; a 
generous gift from Dr Trevor Littlewood, Department of Biochemistry, University of Cambridge) was 
established. Cells were cultured (100 μl final volume per well) in 96-well flat-bottom cell culture plates 
using Dulbecco’s Modified Eagle Medium (DMEM; Life Technologies) with 10% (v/v) fetal bovine 
serum (FBS; Life Technologies) at 37 °C in a humidified incubator with 5% CO2. When the confluence 
of cells reached 80%, 33 ng of pGL3-CAGA (with myostatin responsive firefly luciferase reporter) and 
17 ng of pRL-SV40 (Promega, with constitutively expressed Renilla luciferase) plasmids were mixed 
with 0.2 μl of FuGENE HD transfection reagent (Promega), and added to each well. 24 hours post-
transfection, cell culture medium was removed, and replaced with DMEM containing 0.5% FBS and 
an appropriate dilution of myostatin, or one of its pro-forms. Each concentration point was repeated in 
triplicate. For pro-domain inhibition assays, purified wild-type and mutant variant MBP-prodomain 
fusions were serially diluted (0-100 nM) into DMEM containing 0.5% FBS and 0.25 nM mature 
myostatin, before adding to cells as above. 
After overnight incubation in protein containing medium, cells were washed with PBS and lysed by 
addition of 20 μl Passive Lysis Buffer (Promega, USA), and shaking at room temperature for 15 
minutes. A volume of 4 μl of cell lysate from each well was transferred into a black flat-bottomed half-
area 96-well plate. PHERAstar microplate reader (BMG LABTECH, Germany) was used to inject 15 
µL of Firefly luciferase substrate (LAR II, Promega, USA) per well, and measure resulting 
luminescence for 2 seconds after a 4-second delay. A volume of 15 μl of Stop & Glo Reagent (Promega) 
was then added into each well to quench the firefly luciferase signal and to provide substrate for the 
Renilla luciferase. Renilla luminescence measurements were measured as for Firefly luciferase. Firefly 
luminescence measurements were normalised against the Renilla luminescence. Non-linear curve 
fitting for EC50 and IC50 calculations were made using a variable slope (four parameters) dose response 
model in GraphPad Prism 7. 
Bioactivity assessment of pro-myostatin polymorphisms in HEK293 cells 
HEK293 cells stably transfected with SMAD–responsive (CAGA12) luciferase-reporter gene were 
seeded at 20000 cells per well in 100 µl growth media into 96-well poly-D-Lys coated plates (655940 
Greiner Bio-One GmbH, Germany) and grown until confluency of 75-85%. Cells were transfected with 
25 ng pSF-CMV-FMDV IRES-Rluc bearing pro-myostatin variants, 50ng Furin DNA (pcDNA4) and 
25ng human Tolloid-like 2 (pcDNA3 5) in OPTI-MEM reduced serum media (31985-070, Gibco, Life 
Technologies, USA).  TransIT-LT1 Reagent was utilized for transfection (MIR 2300, Mirus Bio LLC, 
USA), 25µL transfection-reaction was added per well directly to the growth media and incubated (37°C, 
5% CO2).  
Six hours post transfection the media was removed and replaced with 100 µL serum-free media. 30 
hours post transfection the cells were lysed using 20 µL per well 1x Passive Lysis Buffer (E1941, 
Promega, USA) with shaking (800 rpm, 20min, room temp.). Lysates were transferred to opaque black 
and white 96 well plates, and 40 µL of LAR II (Promega) was added, Firefly luminescence was recorded 
on Synergy H1 Hybrid Plate Reader (BioTek). Subsequently, 40 µL of Stop & Glo substrate (Promega) 
was added and Renilla luminescence was recorded. Firefly luminescence was normalized against 
Renilla luminescence. Signalling measurements for each pro-myostatin variant was repeated in 
triplicate, and the entire experiment run three times independently. 
Biolayer interferometry 
To analyse the dissociation of mature growth factors from their pro-domains, biolayer interferometry 
(BLI) experiments were performed using ForteBio Octet RED96 (Pall Fortebio, USA). As the pro-
domains carry an N-terminal His-tag, the uncleaved pro-forms and cleaved complexes of pro-myostatin 
and pro-activin A were loaded onto the anti-penta-HIS (HIS1K) biosensors at the concentration of 20 
µg/ml for 90 seconds. The immobilised biosensors were then immersed in kinetic buffer (PBS with 
0.1% BSA and 0.02% Tween-20) with or without 500 nM follistatin-288 to observe the dissociation for 
900 seconds. Follistatin-288 was expressed and purified as per Harrington et al, 2006 (Harrington et al, 
2006). 
Size-exclusion chromatography multi-angle light scattering (SEC-MALS) 
SEC-MALS analysis was conducted using Superdex 200 Increase 10/300 column (GE Healthcare) with 
DAWN HELEOS II light scattering detector  and Optilab T-rEX refractive index detector (Wyatt 
Technology, USA). Bovine serum albumin (Thermo Scientific) was used for calibration of the system 
in 20 mM Tris pH 8.0, 150 mM NaCl) before 100 μl of sample at a concentration of 1-1.5 mg ml−1 was 
analysed. Experimental data was recorded and processed using ASTRA (Wyatt Technology) software. 
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TABLES 
Table 1. Crystallographic data collection, processing and refinement statistics 
Description: Pro-MSTNΔ43-mut  Pro-MSTNΔ43 
PDB code:  5NTU 5NXS 
Data collection   
Synchrotron / beamline DLS / I-03 DLS / I-03 
X-ray wavelength [Å] 0.97625 0.97970 
Data processing *   
Space group  C 1 2 1      I 2 3        
Unit cell (a, b, c) [Å) 168.16, 36.30, 120.45 196.83, 196.83, 196.83 
γ [°] 90.0, 104.4, 90.0 90.0, 90.0, 90.0 
Resolution limits [Å]† 76.26-2.58 (2.62-2.58) 98.41-4.19 (4.27-4.19) 
Number of protomers in ASU  2 2 
No of total / unique reflections  90386 / 22474 1517107 / 9470 
Multiplicity  4.0 (4.2) 160.2 (128.0) 
Rmerge  0.056 (0.826) 0.141 (2.690) 
Rmeas  0.071 (1.037) 0.148 (2.732) 
I/I  11.7 (1.3) 28.6 (3.0) 
CC1/2  0.997 (0.583) 0.996 (0.923) 
Completeness [%] 97.7 (99.6) 100.0 (100.0) 
Anomalous completeness [%]  100.0 (100.0) 
Anomalous multiplicity  84.0 (66.0) 
Anomalous signal ( |DANO|/(DANO) )  2.089 (7.368)‡ 
Refinement   
Rwork/Rfree [%]  0.215/ 0.260  0.274 / 0.301 
No. of unique/free reflections used  22310/ 1118  9460 / 478 
R.m.s deviations:    
    bond lengths [Å] 0.010 0.010 
    bond angles [°] 0.55 0.53 
Ramachandran analysis: (no. / %  of residues)   
    Most favoured   535 / 95 %  452 / 88 % 
    Allowed   23 / 4 %  58 / 11 % 
    Outliers   4 / 1 %  5 / 1 % 
Number of atoms/B-factors:   
    Protein atoms 4404 / 100.5 3556 / 91.7 
    Solvent atoms  30 / 76.0 0 / - 
    Heterogen atoms  86 / 90.8 0 / - 
Mean/Wilson B-factor  100.2/ 95.7 91.7/ 225.3 § 
* Processing statistics are shown for data merged from 7 crystals 
† Data in parenthesis are for the highest resolution shell. 
‡ Data in parenthesis are for the low resolution shell (98.41-11.38 Å) 
§ The Wilson B-factor is ill-defined due to the low resolution of this structure 
FIGURE LEGENDS 
 
Figure 1. Characterisation of recombinant pro-myostatin. A. SEC-MALS analysis of pro-myostatin 
(black line), and HRV-3C cleaved pro-myostatin complex (blue line). Loaded samples are shown on 
inset gels. The cleaved complex elutes from size-exclusion chromatography column at the same volume 
as the uncleaved precursor (solid lines), indicative of stable complex formation between mature GF 
dimer and two pro-domains. Molecular mass analysis by light scattering is shown as dashed lines across 
the peaks, with molar mass values on the right-hand Y axis. B. Myostatin signalling response in 
HEK293T cells as determined by luciferase reporter assay. Purified mature GF domain is more than 
100 times as potent as the 'latent' HRV-3C cleaved complex, while uncleaved pro-myostatin shows no 
signalling activity. Data points represent the mean of triplicate measurements (duplicate only for 
uncleaved pro-myostatin) and error bars show s.d. 
Figure 2. A. Small-angle X-ray scattering intensity (I) vs q for pro-myostatin and HRV-3C cleaved 
complex. Scattering curves overlay well, with little change in the estimated radius of gyration (Rg) 
following cleavage of the pro-domain. B. Inter-atomic pair distribution functions P(r) calculated by 
DATGNOM (qmax ≈ 0.2) for pro-myostatin and HRV-3C cleaved pro-myostatin complex. P(r) functions 
approach zero smoothly at Dmax=140.6 Å and 146.6 Å for uncleaved and cleaved pro-myostatin 
respectively. C. Dissociation of mature myostatin GF from cleaved pro-myostatin complex using 
biolayer interferometry. The complex is immobilised on sensor tip through N-terminal His-tag using an 
anti-penta-His antibody and dissociation of the mature domain monitored for 900 seconds in absence 
(blue line) and presence (red line) of 500 nM FST-288.  D. Same experiment shown in E. but monitoring 
dissociation of pro-activin A complex.  
Figure 3. Structure of unprocessed human pro-myostatin. A. 2.6 Å crystal structure of unprocessed pro-
myostatin dimer showing mature GF dimer (orange/light grey) with bound pro-domains (red/dark grey). 
Unmodelled loop regions are shown as dashed lines. B. Pro-myostatin chain coloured by rainbow from 
N-terminus (blue) to C-terminus (red). Second chain of the dimer is coloured grey. 
Figure 4. Conformational flexibility of pro and mature myostatin. A. High (red) and low (grey) 
resolution pro-myostatin structures aligned by a single mature GF protomer, showing shift in inter-
protomer angle. B. Ab initio SAXS envelope (DAMFILT) of unprocessed pro-myostatin, with docked 
pro-myostatin structure (PDB: 5NTU). C. Mature myostatin GF dimers from structures solved to date, 
showing inter-protomer plasticity (individual protomers coloured orange and pale orange). D. 
Comparison of pro-myostatin with the architectures of known pro-forms of TGF- superfamily growth 
factors.  
Figure 5. Key pro-domain interactions A. Interaction of N-terminal forearm of pro-myostatin (red) with 
mature GF domain (orange). Forearm residues within 4.5Å of mature GF are shown as sticks. Residues 
fully conserved between pro-myostatin, pro-TGF-β1 and pro-activin A are coloured yellow. B. N-
terminal α1 helix interactions with mature GF. C. Fastener residue interactions and proximity to the 
furin cleavage site (blue). D. Details of fastener stacking interaction, with electron density contoured to 
1σ. E. α2 helix interactions with the convex surface of GF finger. F. Sequence alignment of N-terminal 
forearm regions (starting at first residue following signal peptide cleavage site). Alignment numbering 
and secondary structure annotation is based on the sequence and structure of pro-myostatin. The 
secondary structure of this section of the protein is shown above the aligment with the dashed line 
depicting the part of the sequence that is not present in the crystallisation construct. Conservation of the 
sequences is indicated by the darkness of the background blue colour for each residue. Pro-myostatin 
α1 helix residues involved in GF interaction are indicated with red arrowheads and the TLD cleavage 
site with a black arrowhead.  
Figure 6. Pro-domain arm interactions. A. Surface representation of mature GF protomers (orange) and 
pro-domain forearms (red, blue or green) showing the pro-domain arm interaction surface area (white, 
calculated using PyMOL). B. Extended hydrogen bonding (dashed lines) between the pro-domain arm 
(red) and mature domain (orange) with stick models of the two strands overlaid on cartoon 
representation of the same structure. C. The forearm (red) interaction with the mature GF (orange) is 
stabilised by interaction of the α1 helix with arm (grey) at the fastener, and by lasso interaction with 
loop β6/β7 of the arm domain. This binding mode completely encircles the GF finger, and occludes 
both putative receptor sites. For simplicity, only a single protomer is shown.  
Figure 7. Pro-myostatin structural polymorphisms. A. Selected residues with known human missense 
polymorphisms and/or possible role in pro-mature interactions and latency of pro-myostatin. B. 
Signalling activity of pro-myostatin variants expressed in HEK293 cells stably transfected with SMAD–
responsive (CAGA12) luciferase-reporter gene and co-expressing furin protease and human tolloid-like 
2 protease to facilitate activation. Signalling measurements (luciferase readout) for each pro-myostatin 
variant was repeated in triplicate, and the entire experiment run three times independently (data shown 
are means ± SEM). C. Inhibition of mature myostatin signalling by E. coli expressed pro-domains, 
determined using myostatin responsive luciferase reporter assay (in presence of 0.25 nM mature 
myostatin). Data are normalised to 100% activity and represent the mean of triplicate measurements 
(error bars show s.d). 
Figure 8. Model for myostatin biosynthesis and activation.  The diagrams shows schematically different 
stages of myostatin biosynthesis (A-C), the features of the latent precursor (D) and the sequential 
activation of the pro-myostatin by furin and TLD (E-F), dissociation of the complex (G-H) and release 
of the mature GF (I).  
 
EXPANDED VIEW FIGURE LEGENDS 
 
Figure EV1. BLI analysis of pro-myostatin and pro-activin A precursors. A. Dissociation of pro-
myostatin precursor from BLI sensor tips, immobilised through the N-terminal His-tag, in the absence 
(blue line) and presence (red line) of FST288, showing no significant difference between the two 
conditions. B.  Dissociation of pro-activin A precursor from BLI sensor tips, immobilised through the 
N-terminal His-tag, in the absence (blue line) and presence (red line) of FST288, showing significant 
increase in the signal for the FST288 containing sample, suggesting that FST288 can interact with 
mature domain of pro-activin A even before a proteolytic cleavage releases the mature growth factor 
from its pro-peptide. 
Figure EV2. Low resolution pro-myostatin structure. Anomalous difference density (green mesh, 
contoured at 5.0 σ) for selenium atoms in seleno-methionine residues from the SAD phasing of the low-
resolution pro-myostatin structure.  
Figure EV3. B-factor analysis of the 2.6 Å pro-myostatin structure. The backbone of the pro-myostatin 
structure is represented as variable thickness tube in which the thickness and colour vary according to 
the B-factor of the residue, with thin blue tube showing the lowest B-factors and thick red tube the 
highest B-factors.  
Figure EV4. Proposed forearm-arm connectivity. The top figure shows the proposed domain-swapped 
connectivity for pro-myostatin with one of the protomers shown as a red and beige tube, with the furin 
recognition site coloured blue (second protomer coloured white). The missing residues from the Tolloid 
cleavage site/linker are represented with red spheres. The bottom figure shows the two possible 
connectivities from the α2-helix to the arm domain (dashed lines) with the linear distance between the 
last residues in the α2-helix and the first residue of the arm domain shown in red for domain-swapped 
architecture and in black for the alternative non domain-swapped arrangement.  
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Appendix Figure S1. SAXS Guinier plots (SCATTER 3.0) show no deviation from linearity at low q values and 
unbiased distribution of residuals for uncleaved and cleaved pro-myostatin, suggesting samples are free from 
aggregation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix Figure S2.  Pro-myostatin variant signalling in HEK293 cells stably transfected with SMAD–responsive 
(CAGA12) luciferase-reporter gene. When expressed in cells transfected with only 5 ng human Tolloid-like 2 (hTLL-2), 
pro-myostatin complexes showed very little signalling activity (Raw data A & wild-type normalised C). When 25 ng 
hTLL-2 was co-transfected, wild-type signalling activity was considerably higher, and several variants show marked 
increase in signalling over the wild-type (raw data B & wild-type normalised D). The wild-type normalised signalling 
data (from C and D) has been replot to show the ratio of activity for 25 ng/5 ng hTLL-2 transfection experiments (E). 
Several pro-myostatin variants show proportionally higher activity with increased hTLL-2 co-expression than other 
variants. Signalling measurements for each pro-myostatin variant was repeated in triplicate, and the entire experiment 
run three times independently (data shown are means ± SEM). Error bars are not shown for E as this plot shows the ratio 
of calculated mean values from C and D. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix Figure S3. SDS-PAGE (Coomassie stained) analysis of purified MBP-prodomain constructs. 
 
 
Appendix Table S1: Crystallographic data from crystals used for the merged dataset for phasing. All data were collected in a single session at Diamond 
Light Source, beamline I-03 at a wavelength of 0.9797 Å. 
 
 
(*Values for high resolution shell are given in parenthesis for indication only; all integrated data were used during merging) 
(** values in parenthesis are given for the low resolution shell) 
Data processing*:  Crystal 1 Crystal 2 Crystal 3 Crystal 4 Crystal 5 Crystal 6  Crystal 7 merged 
Spacegroup  I 2 3 I 2 3 I 2 3 I 2 3 I 2 3 I 2 3 I 2 3 I 2 3 
Unit cell (a, b, c [Å],  197.28 197.28 
197.28 
197.01 197.01 
197.01 
196.39 196.39 
196.39 
196.42 196.42 
196.42 
195.80 195.80 
195.80 
198.46 198.46 
198.46 
196.70 196.70 
196.70 
196.83 196.83 
196.83 
α,β,γ [°])  90.0 90.0 90.0 90.0 90.0 90.0 90.0 90.0 90.0 90.0 90.0 90.0 90.0 90.0 90.0 90.0 90.0 90.0 90.0 90.0 90.0 90.0 90.0 90.0 
Resolution limits [Å]  98.640-4.204 
(4.277-4.204) 
80.431-4.320 
(4.394-4.320) 
98.194-4.372 
(4.447-4.372) 
138.891-4.309 
(4.383-4.309) 
138.454-4.302 
(4.376-4.302) 
99.230-4.278 
(4.352-4.278) 
139.084-4.201 
(4.274-4.201) 
98.41-4.19 
(4.27-4.19) 
No of total/unique 
reflections  
340350 / 9470 269893 / 8707 147990 / 8323 180483 / 8705 134953 / 8673 77422 / 9148 342136 / 9403 1517107 / 9470 
Multiplicity 35.9 (30.6) 31.0 (26.2) 17.8 (15.0) 20.7 (17.3) 15.6 (13.3) 8.5 (7.3) 36.4 (30.9) 160.2 (128.0) 
Rmerge  0.122 (1.694) 0.107 (2.933) 0.096 (2.022) 0.105 (1.840) 0.086 (1.576) 0.082 (1.002) 0.105 (2.193) 0.141 (2.690) 
Rmeas  0.124 (1.722) 0.109 (2.990) 0.099 (2.093) 0.107 (1.895) 0.089 (1.639) 0.087 (1.079) 0.107 (2.229) 0.148 (2.732) 
I/σI  15.4 (1.8) 16.6 (1.3) 15.1 (1.3) 14.3 (1.5) 14.9 (1.4) 12.6 (1.4) 17.9 (1.6) 28.6 (3.0) 
CC1/2  0.997 (0.865) 1.000 (0.702) 0.999 (0.604) 1.000 (0.701) 0.999 (0.722) 0.998 (0.977) 0.999 (0.706) 0.996 (0.923) 
Completeness [%]  100.0 (100.0) 100.0 (96.6) 100.0 (100.0) 100.0 (100.0) 100.0 (100.0) 99.9 (100.0) 100.0 (100.0) 100.0 (100.0) 
         
anomalous 
completeness  [%]  
100.0 (100.0) 100 (96.3) 100.0 (100.0) 100.0 (100.0) 100.0 (100.0) 99.8 (100.0) 100.0 (100.0) 100.0 (100.0) 
anomalous 
multiplicity 
18.8 (15.8) 16.2 (13.6) 9.3 (7.7) 10.9 (9.0) 8.2 (6.9) 4.4 (3.8) 19.1 (16.0) 84.0 (66.0) 
Anomalous signal  
( |DANO|/sd(DANO) )  
1.288 
(3.911)** 
1.395 
(5.007)** 
1.359 
(4.986)** 
1.319 
(4.198)** 
1.330 
(4.579)** 
1.267 
(3.394)** 
1.378 
(4.614)** 
2.089  
(7.368)** 
 
 
Appendix Table S2. Missense mutations in pro-myostatin from Ensembl database (Ensembl genome 
assembly GRCh38.p10, accessed on 05.06.2017) with a scoring of possible effect on myostatin activity 
based on visual analysis of all the mutated positions in the structure.  
 
Scoring key 
0 residue not visible or not part of the crystallisation construct 
1 no effect 
2 possible effect 
3 likely effect  
4 Highly likely effect  
Mutation  Chain A Chain B 
Domain/ 
feature Comment 
Q2K 0 0 Signal peptide  
V8I 0 0 Signal peptide  
Y11H 0 0 Signal peptide  
M14T 0 0 Signal peptide  
M14I 0 0 Signal peptide  
I16T 0 0 Signal peptide  
A18S 0 0 Signal peptide  
G19D 0 0 Signal peptide  
E25K 0 0 Forearm  
N26H 0 0 Forearm  
E28K 0 0 Forearm  
Q29K 0 0 Forearm  
K30T 0 0 Forearm  
T43I 0 1 Forearm  
W44R 0 2 Forearm  
R45K 0 1 Forearm  
K49E 1 2 Forearm  
R52K 3 3 Forearm Removal of a hydrogen bond 
I53K 1 1 Forearm  
E54K 1 2 Forearm  
A55T 1 1 Forearm  
A55T 1 1 Forearm  
Q59R 2 2 Forearm  
R65C 3 3 Forearm Disruption of the fastener, introduction of a lone cysteine 
R65H 3 3 Forearm Disruption of the fastener 
E67K 1 1 Forearm  
K74R 1 1 Forearm  
L80V 2 2 Forearm  
A84G 3 3 Forearm Removal of an apolar interaction 
R88Q 1 1 Forearm  
I91T 3 3 Forearm Polar substitution in an apolar site 
D95H 0 1 Forearm Close to Tolloid recognition site  
R98S 0 0 Tolloid linker Close to Tolloid recognition site  
D99G 0 0 Tolloid linker Mutation of Tolloid recognition site  
D103N 0 0 Tolloid linker  
L106F 1 0 Tolloid linker  
D109E 1 1 Tolloid linker  
D110N 1 2 Tolloid linker  
Y111H 3 3 Fastener Loss of pi-cation interaction 
 
 
H112R 3 3 Fastener Loss of stacking in the fastener 
T114A 1 1 Shoulder  
T115M 2 2 Shoulder  
M121T 3 3 Shoulder Removal of hydrophobic residue 
M129R 0 0 Shoulder  
V131A 0 0 Shoulder  
K136Q 0 1 Shoulder  
K136R 0 1 Shoulder  
C138F 2 2 Shoulder  
S144F 2 2 Shoulder  
Y148C 1 1 Shoulder  
K153R 1 1 Shoulder  
K153R 1 1 Shoulder  
A154T 1 1 Shoulder  
L156I 1 1 Shoulder  
L156I 1 1 Shoulder  
R161I 1 1 Shoulder  
R161S 1 1 Shoulder  
E164K 1 1 Shoulder  
E164K 1 1 Shoulder  
P166S 1 1 Shoulder  
T167A 1 1 Shoulder  
Q172R 1 1 Shoulder  
Q172H 1 1 Shoulder  
Q172H 1 1 Shoulder  
I177L 1 1 Shoulder  
I177T 1 1 Shoulder  
I177M 1 1 Shoulder  
M180T 1 0 Shoulder  
M180V 1 0 Shoulder  
G183R 1 0 Shoulder  
T184I 1 0 Shoulder  
R185T 1 1 Shoulder  
T187N 1 1 Shoulder  
P188A 1 1 Shoulder   
R190Q 1 1 Shoulder  
R190L 1 1 Shoulder  
M196L 1 1 Shoulder  
M196V 1 1 Shoulder  
G201D 1 1 Shoulder  
S205I 1 1 Shoulder  
D207H 1 1 Shoulder  
T210I 1 1 Shoulder  
L212M 1 1 Shoulder  
N222S 1 0 Shoulder  
I225V 1 1 Shoulder  
I225T 1 1 Shoulder  
D236V 1 1 Shoulder  
A238T 1 1 Shoulder  
A238V 1 1 Shoulder  
T240N 1 1 Shoulder  
 
 
F241L 1 1 Shoulder  
P242S 2 2 Shoulder  
P244A 2 2 Shoulder  
L249P 2 2 Shoulder  
N250D 2 2 Shoulder  
P251L 1 1 Shoulder  
K256M 1 1 Shoulder  
V257L 1 1 Shoulder  
P261S 1 0 Shoulder  
R265K 1 0 Shoulder  
G269R 1 1 Growth factor  
G269D 1 1 Growth factor  
D273V 1 1 Growth factor  
E274K 1 2 Growth factor  
T277A 1 1 Growth factor  
R280Q 1 1 Growth factor  
R283H 2 1 Growth factor  
D289E 1 1 Growth factor  
A292G 1 1 Growth factor  
D296E 2 2 Growth factor  
K305E 1 1 Growth factor  
K305N 1 1 Growth factor  
N307S 1 1 Growth factor  
E312D 1 1 Growth factor  
F317L 2 0 Growth factor  
V327I 2 0 Growth factor  
H328N 1 1 Growth factor  
P332L 2 0 Growth factor  
P338R 2 1 Growth factor  
C340R 4 4 Growth factor Disruption of a disulfide bridge 
M345L 1 1 Growth factor  
I348T 1 1 Growth factor  
N354H 2 2 Growth factor  
N354D 2 2 Growth factor  
Q358K 3 2 Growth factor  
Y361F 3 3 Growth factor  
G362E 3 3 Growth factor  
P365T 3 3 Growth factor  
P365L 3 3 Growth factor  
A366V 2 2 Growth factor  
R371G 1 2 Growth factor  
R371C 1 2 Growth factor  
R371L 1 2 Growth factor  
G373R 2 2 Growth factor  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Appendix Table S3. Non-linear fitting derived parameters of pro-domain inhibition of myostatin GF. 
Parameters calculated using a variable slope (four parameters) dose response model in GraphPad 
Prism 7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
IC50 (nM) IC50 CI (95%) Hillslope Hillslope CI (95%) 
Wild-type pro 0.94 0.83 – 1.08 -2.02 -2.79  –   -1.53 
R65A pro 1.64 1.42 – 1.91 -2.24 -2.93  –   -1.74 
A84G pro 1.35 1.18 – 1.54 -1.99 -2.55  –   -1.57 
Y111H pro 1.00 0.88 – 1.14 -1.86 -2.42  –   -1.45 
H112R pro 1.10 0.95 – 1.28 -1.92 -2.60  –   -1.46 
K153R pro 1.20 1.01 – 1.41 -1.95 -2.78  -–  -1.41 
 
 
 
Appendix Table S4. Oligonucleotides used for cloning.  
 
Cloning of full length pro-myostatin construct  
    
Forward oligo (BamHI)  5' TATATGGATCCGACCAGTAGATCTAAATGAGAAC 3' 
Reverse oligo (NotI) 5' TATATAGCGGCCGCTTATGAGCACCCACAGCGGTCTACTAC 3' 
  
Introduction of N-terminal TEV cleavage site 
    
Forward oligo 5' AACCTGTATTTTCAGGGCTCCACTTGGAGACAAAACACTAAA 3' 
Reverse oligo  5' GCCCTGAAAATACAGGTTCTCTTTTTCCACATTTTCTTT 3' 
  
Mutagenesis of furin cleavage site to HRV-3C site 
    
Forward oligo 5' CTAGAAGTACTATTTCAAGGACCAGACTGTGATGAGCACTCAACA 3' 
Reverse oligo  5' TGGTCCTTGAAATAGTACTTCTAGTTTTGGTGTGTCTGTTACCTT 3' 
  
Surface entropy mutations (K217A, Q218A, E220A) 
    
Forward oligo 5' CAAAATTGGCTCGCGGCGCCTGCGTCCAACTTAGGC 3' 
Reverse oligo  5' GCCTAAGTTGGACGCAGGCGCCGCGAGCCAATTTTG 3' 
  
Surface entropy mutations (G319A, K320A) 
    
Forward oligo 5' GAATTTGTATTTTTAGCGGCGTATCCTCATACTCAT 3' 
Reverse oligo  5' ATGAGTATGAGGATACGCCGCTAAAAATACAAATTC 3' 
  
Cloning mammalian constructs (pSF-CMV-FMDV-Rluc vector) 
  
Forward oligo (NcoI) 5’ ACGCCATGGATGCAAAAACTGCAACTCTG 3’ 
Reverse oligo (EcoRV) 5’ CGTATGATATCTCATGAGCACCCACAGCGG 3’ 
  
Cloning MBP-pro-domain fusion for bacterial expression 
  
Forward oligo (BamHI) 5' ACGGGATCCAATGAGAACAGTGAGCAAAAAGAAAATGTGG 3' 
Reverse oligo (EcoRI) 5' TATGAATTCTCATTTTGGTGTGTCTGTTACCTTGAC 3' 
  
Solubility improving pro-domain cysteine substitutions  
  
C39S_C42S Forward oligo 5’ GGAAAAAGAGGGGCTGTCTAATGCATCTACTTGGAGACAAAAC 3’ 
C39S_C42S Rev Reverse oligo 5' GTGTTTTGTCTCCAAGTAGATGCATTAGACAGCCCCTCTTTTTCC 3' 
 
 
C137S_C138S_Forward oligo 5’ GGAAAACCCAAATCTAGCTTCTTTAAATTTAGC 3’ 
C137S_C138S_Reverse oligo 5’ GCTAAATTTAAAGAAGCTAGATTTGGGTTTTCC 3’ 
 
 
 
 
 
Prodomain mutations     
  
R65A Forward oligo 5' ATCCTCAGTAAACTTGCTCTGGAAACAGCTCC 3' 
R65A Reverse oligo 5' AGGAGCTGTTTCCAGAGCAAGTTTACTGAGG 3' 
  
R65C Forward oligo 5' ATCCTCAGTAAACTTTGTCTGGAAACAGCTCC 3' 
R65C Reverse oligo 5' AGGAGCTGTTTCCAGACAAAGTTTACTGAGG 3' 
  
A84G Forward oligo 5' ACTTTTACCCAAAGGTCCTCCACTCCGG 3' 
A84G Reverse oligo 5' TCCCGGAGTGGAGGACCTTTGGGTAAAAG 3' 
  
Y111H Forward oligo 5' GAAGATGACGATCACCACGCTACAACGG 3' 
Y111H Reverse oligo 5’ TCCGTTGTAGCGTGGTGATCGTCATCTTCC 3' 
  
H112R Forward oligo 5' AGATGACGATTATCGAGCTACAACGGAAAC 3' 
H112R Reverse oligo 5' TGTTTCCGTTGTAGCTCGATAATCGTCATCTTCC 3' 
  
K153R Forward oligo 5' AATAAAGTAGTAAGGGCCCAACTATGGATATAT 3' 
K153R Reverse oligo 5' CCATAGTTGGGCCCTTACTACTTTATTGTATTG 3' 
 
 
W203A Forward oligo 5' AGGCACTGGTATTGCTCAGAGCATTGATG 3' 
W203A Reverse oligo 5' ATCAATGCTCTGAGCAATACCAGTGCC 3' 
  
W203F Forward oligo 5' AGGCACTGGTATTTTTCAGAGCATTGATG 3' 
W203F Reverse oligo 5' ATCAATGCTCTGAAAAATACCAGTGCC 3' 
  
W203H Forward oligo 5' AGGCACTGGTATTCACCAGAGCATTGATG 3' 
W203H Reverse oligo 5' ATCAATGCTCTGGTGAATACCAGTGCC 3' 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
